MARLBOROUGH, Mass., May 26, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 11:30 a.m. EDT. Dr. Cauwenbergh will present a corporate overview, including multiple business development opportunities available based on RXi's proprietary sd-rxRNA® platform and extensive intellectual property portfolio.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

The presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com. 

About Jefferies 2015 Global Healthcare Conference

This conference will feature an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors, with over 300 participating companies and 2,500 attendees. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally. The four day conference will be comprised of company presentations, Q&A breakout sessions and thematic panels. Company management teams and investors will also have the opportunity to participate in 1x1 and small group meetings. This conference will take place June 1-4, 2015 in New York City.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the area of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents.  These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma. 

RXi's novel, self-delivering RNAi (sd‑rxRNA) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. Sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity. 

RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and retina and is currently being evaluated in Phase 2a clinical trials. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.

RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about future expectations and planned and future development of our product candidates, technologies and partnerships.  Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-jefferies-2015-global-healthcare-conference-300088408.html

SOURCE RXi Pharmaceuticals Corporation

Copyright 2015 PR Newswire

RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more RXI Pharmaceuticals Corporation Charts.